Conception and design: Claire Gallois, Qian Shi, Steven R Alberts, Daniel G. Haller, Anthony Frank Shields, Rachel Kerr, Ioannis Boukovinas, Roberto Labianca, Takayuki Yoshino, Julien Taieb

Administrative support: Qian Shi, Greg Yothers

Provision of study materials or patients: Steven R Alberts, Alberto F. Sobrero, Anthony Frank Shields, Ioannis Souglakos, Thierry André

Collection and assembly of data: Claire Gallois, Qian Shi, Jeffrey P. Meyers, Steven R Alberts, Aimery de Gramont, Alberto F. Sobrero, Eiji Oki, Anthony Frank Shields, Rachel Kerr, Greg Yothers, Caroline Kelly, Ioannis Boukovinas, Roberto Labianca, Ioannis Souglakos, Takayuki Yoshino, Jeffrey A Meyerhardt, Thierry André, Julien Taieb

Data analysis and interpretation: Claire Gallois, Qian Shi, Jeffrey P. Meyers, Timothy Iveson, Steven R Alberts, Alberto F. Sobrero, Daniel G. Haller, Anthony Frank Shields, Richard M Goldberg, Rachel Kerr, Sara Lonardi, Greg Yothers, Ioannis Boukovinas, Roberto Labianca, Takayuki Yoshino, Jeffrey A Meyerhardt, Thierry André, Demetris Papamichael, Julien Taieb

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Claire Gallois

Consulting or Advisory Role: Servier

Travel, Accommodations, Expenses: Amgen

Qian Shi

Honoraria: Chugai Pharma

Consulting or Advisory Role: Yiviva, Boehringer Ingelheim, Regeneron, Hoosier Cancer Research Network, Kronos Bio

Research Funding: Celgene (Inst), Roche/Genentech (Inst), Janssen (Inst), BMS (Inst), Novartis (Inst)

Jeffrey P. Meyers

Employment: Regeneron

Stock and Other Ownership Interests: Regeneron

Timothy Iveson

Honoraria: Servier, Amgen

Consulting or Advisory Role: Servier, Bristol Myers Squibb, Pierre Fabre, MSD Oncology

Alberto F. Sobrero

Stock and Other Ownership Interests: Bayer

Consulting or Advisory Role: Roche, Merck Serono, Servier, Sanofi, Celgene, Amgen, Bayer, Menarini

Speakers' Bureau: Sanofi, Merck Serono, Takeda, Roche, Bayer, Amgen, Celgene, Lilly, AstraZeneca, Bristol Myers Squibb

Travel, Accommodations, Expenses: Bayer, Merck Serono, Roche, Takeda

Eiji Oki

Speakers' Bureau: Chugai Pharma, Lilly Japan, Takeda, Ono Pharmaceutical, Bristol Myers Squibb Japan

Anthony Frank Shields

Consulting or Advisory Role: ImaginAb, Caris Life Sciences, Cogent Biosciences

Speakers' Bureau: Caris Life Sciences

Research Funding: Taiho Pharmaceutical, Bayer, Boehringer Ingelheim, Plexxikon, Eisai, Inovio Pharmaceuticals, H3 Biomedicine, Caris Life Sciences, ImaginAb, Exelixis, Xencor, Lexicon, Daiichi Sankyo, Halozyme, Incyte, LSK BioPharma, Esperas Pharma, Nouscom, Boston Biomedical, Astellas Pharma, AstraZeneca, Five Prime Therapeutics, MSK Pharma, Alkermes, Repertoire Immune Medicines, Telix Pharmaceuticals, Hutchison China Meditech, Seattle Genetics, Jiangsu Alphamab Biopharmaceuticals, Shanghai HaiHe Pharmaceutical, TopAlliance BioSciences Inc (Inst), Gritstone Bio (Inst), SQZ Biotechnology (Inst)

Travel, Accommodations, Expenses: GE Healthcare, Caris Life Sciences, TransTarget, ImaginAb, Inovio Pharmaceuticals

Richard M. Goldberg

Stock and Other Ownership Interests: Advanced Chemotherapy Technologies

Consulting or Advisory Role: Taiho Pharmaceutical, AstraZeneca, Bayer, G1 Therapeutics, Compass Therapeutics, UpToDate, Eisai/H3 Biomedicine, Sorrento Therapeutics, Adaptimmune, IQvia, GlaxoSmithKline, Merck

Expert Testimony: Taiho Pharmaceutical, Genentech/Roche

Sara Lonardi

Consulting or Advisory Role: Amgen, Merck Serono, Lilly, Servier, AstraZeneca, Incyte, Daiichi Sankyo, Bristol Myers Squibb, MSD, Mirati Therapeutics

Speakers' Bureau: Roche, Lilly, Bristol Myers Squibb, Servier, Merck Serono, Pierre Fabre, GlaxoSmithKline, Amgen, Mirati Therapeutics, MSD Oncology

Research Funding: Amgen, Merck Serono, Bayer (Inst), Roche (Inst), Lilly (Inst), AstraZeneca (Inst), Bristol Myers Squibb (Inst)

Greg Yothers

Employment: Mountainview Pediatrics

Consulting or Advisory Role: Orbus Therapeutics

Ioannis Boukovinas

Employment: Pierre Fabre

Honoraria: Roche, MSD, Bristol Myers Squibb, Pfizer, Novartis, Merck, AstraZeneca, LEO Pharma, Servier

Consulting or Advisory Role: Roche, Sanofi, AstraZeneca, Bristol Myers Squibb, LEO Pharma, MSD, Novartis, Ipsen, Genesis Pharma

Research Funding: Roche, Novartis, Bristol Myers Squibb, MSD, Regeneron, Boehringer Ingelheim, Lilly, Pfizer

Travel, Accommodations, Expenses: MSD, Roche, Pfizer, Bristol Myers Squibb, Servier, Ipsen

Roberto Labianca

Consulting or Advisory Role: Roche, Lilly, Sanofi, Merck Serono

Travel, Accommodations, Expenses: Roche, Merck Serono, Servier

Frank A. Sinicrope

Stock and Other Ownership Interests: illumina

Honoraria: Targeted Oncology

Consulting or Advisory Role: Guardant Health

Research Funding: Ventana Medical Systems (Inst)

Patents, Royalties, Other Intellectual Property: Patent royalty related to immune markers in colon cancer. Patent jointly held between myself and Roche/Ventana Medical Systems (Inst)

Travel, Accommodations, Expenses: Guardant Health

Ioannis Souglakos

Consulting or Advisory Role: Roche (Inst), Servier (Inst), IPSEN (Inst), Pierre Fabre, MSD, Bristol-Myers Squibb-Ono Pharmaceutical

Speakers' Bureau: Sanofi, Merck KGaA (Inst), Roche (Inst), MSD

Research Funding: Amgen (Inst), Sanofi (Inst)

Travel, Accommodations, Expenses: Merck Serono, Amgen, Sanofi, Roche, Servier

Takayuki Yoshino

Honoraria: Chugai Pharma, Merck, Bayer Yakuhin, Ono Pharmaceutical, MSD K.K

Research Funding: MSD (Inst), Daiichi Sankyo Company, Limited (Inst), Ono Pharmaceutical (Inst), Taiho Pharmaceutical (Inst), Amgen (Inst), Sanofi (Inst), Pfizer (Inst), Genomedia (Inst), Sysmex (Inst), Nippon Boehringer Ingelheim (Inst), Chugai Pharma (Inst)

Jeffrey A. Meyerhardt

Honoraria: Cota Healthcare, Merck

Research Funding: Boston Biomedical (Inst)

Thierry André

Honoraria: Roche/Genentech, Bristol Myers Squibb, Servier, Amgen, Pierre Fabre, Ventana Medical Systems, GlaxoSmithKline, Merck, Merck Serono, Merck Serono, Sanofi

Consulting or Advisory Role: Amgen, Bristol Myers Squibb, MSD Oncology, Servier, AstraZeneca/MedImmune, Tesaro, Pierre Fabre, GamaMabs Pharma, Astellas Pharma, Kaleido Biosciences, Gritstone Bio, GlaxoSmithKline, Seattle Genetics, Transgene, Nordic Pharma

Travel, Accommodations, Expenses: MSD Oncology

Uncompensated Relationships: ARCAD Foundation, Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group, Gercor

Demetris Papamichael

Honoraria: Amgen, Merck Serono, Ipsen

Research Funding: MSD Oncology

Travel, Accommodations, Expenses: Servier, MSD Oncology

Julien Taieb

Consulting or Advisory Role: Roche, Merck KGaA, Amgen, Servier, MSD, Pierre Fabre, Novartis, AstraZeneca, BMS

Speakers' Bureau: Servier, Amgen, Roche/Genentech, Sanofi, Merck, Lilly, MSD, Pierre Fabre

No other potential conflicts of interest were reported.